AbCellera Biologics vs Bicycle Therapeutics
ABCL and BCYC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABCL and BCYC compare
AbCellera Biologics is the larger company, worth 15 times as much as Bicycle Therapeutics ($3.5B against $236M).
Bicycle Therapeutics grew revenue faster over the last twelve months (195% versus 92.1% for AbCellera Biologics).
Bicycle Therapeutics keeps more of each dollar of sales as profit, with a net margin of −170% compared with −219% at AbCellera Biologics.
Bicycle Therapeutics scores higher on the StockData Score (11 against 8 for AbCellera Biologics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABCL | BCYC |
|---|---|---|
| Size and price | ||
| Market cap | $3.5B | $236M |
| Share price | $11.49 | $3.37 |
| Change, 1 year | 189% | −48.6% |
| Change, 5 years | −27.3% | −94.2% |
| Beta (5Y) | 1.46 | 1.37 |
| Employees | 562 | 288 |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 51.9× | 2.8× (better) |
| P/B | 3.3× | 0.5× (better) |
| FCF yield | −0.93% (better) | −74.9% |
| Fair value | $4.50 | $16.02 |
| Margin of safety | −155% | 79.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 92.1% | 195% (better) |
| Revenue growth, 5Y average | −20.3% | 47.5% (better) |
| Profitability | ||
| Operating margin | −298% | −189% (better) |
| Net margin | −219% | −170% (better) |
| FCF margin | −48.4% (better) | −212% |
| Return on equity | −14.6% (better) | −25.2% |
| Return on invested capital | −41.7% (better) | −4543% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −815.6× |
| Current ratio | 12.43 (better) | 12.09 |
| Altman Z-score | 4.92 (better) | 0.04 |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 37.9% | 53.4% |
| Held by insiders | 22.8% | 21.3% |
| Insider net buying, 12 months | $3.2M (better) | −$523K |
| Short interest, % of float | 12.3% | – |
Go deeper
- ABCL stock overview
- ABCL income statement
- ABCL valuation and score
- BCYC stock overview
- BCYC income statement
- BCYC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.